Follow "the superior mesenteric artery": laparoscopic approach for total mesopancreas excision during pancreaticoduodenectomy.
Laparoscopic pancreaticoduodenectomy
Mesopancreas
Pancreatic cancer
Superior mesenteric artery first approach
Journal
Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
06
03
2019
accepted:
15
07
2019
pubmed:
25
7
2019
medline:
18
7
2020
entrez:
24
7
2019
Statut:
ppublish
Résumé
The prognosis of patients affected by pancreatic adenocarcinoma and periampullary tumors is dismal, mainly due to aggressive tumor biology and low rate of resectability at the diagnosis. Among resectable patients, the quality of surgical resection, with a particular focus on the complete resection of the retropancreatic tissue (the so-called "mesopancreas") encircling the superior mesenteric artery (SMA), has a cardinal role. With this assumption, many pancreatic surgeons recommend periadventitial dissection of the SMA in order to obtain a total mesopancreas excision (TMpE), maximizing surgical margin and minimizing R1 resection rate. To introduce our approaches for periadventitial dissection of the SMA, tailored to patient and tumor characteristics and aiming at obtaining a TMpE, during laparoscopic pancreatoduodenectomy (LPD). Three different approaches for the SMA periadventitial dissection during LPD are described: the right, the right-left, and the anterior SMA-first approach. Indications, advantages, and technical aspects of each technique are reported, as well as pathologic results, particularly focusing on resection margin status and removed lymphnodes number, safety, and feasibility. Overall, R0 rate and number of lymphnodes retrieved were 86% and 26, respectively, without significant differences according to the SMA approach performed. Rate of conversion to laparotomy due to intraoperative bleeding during SMA dissection step was 6% (3/48) among patients who underwent the right SMA approach and nil among remaining patients. During LPD, a tailored approach for periadventitial dissection of SMA makes TMpE feasible, safe, and oncologic valid, when performed by a team experienced with mininvasive approach and pancreatic surgery.
Sections du résumé
BACKGROUND
The prognosis of patients affected by pancreatic adenocarcinoma and periampullary tumors is dismal, mainly due to aggressive tumor biology and low rate of resectability at the diagnosis. Among resectable patients, the quality of surgical resection, with a particular focus on the complete resection of the retropancreatic tissue (the so-called "mesopancreas") encircling the superior mesenteric artery (SMA), has a cardinal role. With this assumption, many pancreatic surgeons recommend periadventitial dissection of the SMA in order to obtain a total mesopancreas excision (TMpE), maximizing surgical margin and minimizing R1 resection rate.
OBJECTIVE
To introduce our approaches for periadventitial dissection of the SMA, tailored to patient and tumor characteristics and aiming at obtaining a TMpE, during laparoscopic pancreatoduodenectomy (LPD).
METHODS
Three different approaches for the SMA periadventitial dissection during LPD are described: the right, the right-left, and the anterior SMA-first approach. Indications, advantages, and technical aspects of each technique are reported, as well as pathologic results, particularly focusing on resection margin status and removed lymphnodes number, safety, and feasibility.
RESULTS
Overall, R0 rate and number of lymphnodes retrieved were 86% and 26, respectively, without significant differences according to the SMA approach performed. Rate of conversion to laparotomy due to intraoperative bleeding during SMA dissection step was 6% (3/48) among patients who underwent the right SMA approach and nil among remaining patients.
CONCLUSION
During LPD, a tailored approach for periadventitial dissection of SMA makes TMpE feasible, safe, and oncologic valid, when performed by a team experienced with mininvasive approach and pancreatic surgery.
Identifiants
pubmed: 31332566
doi: 10.1007/s00464-019-06994-6
pii: 10.1007/s00464-019-06994-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4186-4191Références
Surg Endosc. 2016 Apr;30(4):1670-1
pubmed: 26156616
J Am Coll Surg. 2010 Jul;211(1):142-3
pubmed: 20610264
J Hepatobiliary Pancreat Sci. 2016 Dec;23(12):745-749
pubmed: 27734589
Histopathology. 2008 Jun;52(7):787-96
pubmed: 18081813
Surgery. 2014 Mar;155(3):449-56
pubmed: 24462078
HPB (Oxford). 2016 Apr;18(4):305-11
pubmed: 27037198
Wideochir Inne Tech Maloinwazyjne. 2015 Sep;10(3):450-7
pubmed: 26649095
Arch Surg. 1998 Mar;133(3):297-301
pubmed: 9517744
World J Surg Oncol. 2007 Apr 25;5:44
pubmed: 17459163
J Hepatobiliary Pancreat Sci. 2014 Mar;21(3):E19-21
pubmed: 24307512
Surg Endosc. 1994 May;8(5):408-10
pubmed: 7915434
World J Gastroenterol. 2014 Jun 28;20(24):7864-77
pubmed: 24976723
J Hepatobiliary Pancreat Sci. 2016 Mar;23(3):E5-9
pubmed: 27003875
Eur J Surg Oncol. 2012 Apr;38(4):340-5
pubmed: 22264964
Surg Endosc. 2011 May;25(5):1697-8
pubmed: 20976487
Pancreas. 2016 Apr;45(4):493-502
pubmed: 26954493
Arch Surg. 2010 Jan;145(1):19-23
pubmed: 20083750
Chin J Cancer Res. 2016 Aug;28(4):423-8
pubmed: 27647970
World J Gastroenterol. 2015 Mar 14;21(10):2865-70
pubmed: 25780282
Br J Surg. 2012 Aug;99(8):1027-35
pubmed: 22569924
J Gastrointest Cancer. 2018 Sep;49(3):252-259
pubmed: 28315190
Int J Surg. 2013;11(9):834-6
pubmed: 23994001